The Trading Floor

[mick]

part #10,,,shortages 04/20/04
We Love Stock Momentum!

IMAX has nearly tripled from its lows in February 2003. And our research indicates it should DOUBLE again from here, thanks to the collision of two watershed events in the company's history.

Up until now, their coverage of blockbuster movies has been spotty. They bagged certain key titles, but usually well after the regular release. You were more likely to find IMAX in an urban science museum than your local multiplex.

But that little problem has been solved with a new technology, unveiled in February, that allows IMAX to bring their marvelous, high-depth sound experience to your local multiplex. This is a huge market that was previously off limits.

Even bigger still, IMAX signed a deal with Warner Bros. Pictures to put the two biggest action movies of the year into its venues. And this move should lead other studios to make similar deals with IMAX, in order to give their blockbusters an extra kick with this super format.

With this breakthrough deal the company is building a unique, defensible niche that consumers will flock to by the millions -- just check out the opening week ticket sales on "The Matrix Reloaded" if you need more proof ($134 million in four days!). Buy IMAX below $9, and rake in your share of the profits.

Stock #2: Safety In Numbers

The big pharmaceutical stocks used to be safe enough for "widows and orphans." Not anymore.

Many of them are being run like management doesn't have a clue. Merck is down big. Bristol-Myers Squibb is down big. It's not a pretty picture.

Shrinking pipelines of new drugs. Old drugs coming off patents. The industry is in a shambles.

BUT other drug makers -- generic manufacturers, to be specific -- are really on a roll. The same factors that hamstrung Big Pharma have turned generic drug makers into sales and profit powerhouses.

When Big Pharma's patents expire, the generics step in and clean up. This is a sector you must be in for growth. Plus it's backed by the ever-increasing demands of an aging population (76 million baby boomers, to be exact) -- giving you a great measure of safety, as well. Watch the generics grab more and more market share -- as they stuff your pockets with profits.

At ChangeWave Investing, our top 2 generic picks are up 51% and 118% in just over a year -- and this mighty wave is still growing! Join now and profit with us. Accept a risk-free Trial Membership by going here.

Impax Laboratories (IPXL) is one of our favorites, and a stock I recommend you buy now on dips below $12.50

Impax is a micro-cap company that is ready to break out and is poised to make TONS of cash in the next few years. The company has over 36 different abbreviated new drug applications (ANDAs) filed with the Federal Drug Administration that target a $6 billion market.

Impax has FDA approval to manufacture a 12-hour dosage of Claritin and approval for a 24-hour dosage is pending. As is the case with first-to-market generic drugs, IPXL has a 180-day window of exclusivity for its versions of Claritin. Claritin generic sales have taken over the vast majority of the branded sales in less than six months and AstraZeneca's Prilosec is next.

But there's more to Impax than Claritin and Prilosec. The company has 10 products approved and 36 products pending approval or in development. The company currently has 19 applications pending before the FDA, three with tentative approval and 14 that would be treated as first-to-market generic, which would give it a six-month window of exclusivity. The 19 applications are for drugs facing a market currently worth $5.9 billion.

This one could end up being as huge as our Aceto recommendation (up 100% for us right now). Don't miss your chance for a second rocket ride. Buy IPXL now.

Print Report